2021
The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine
Sagara I, Zongo I, Cairns M, Yerbanga R, Mahamar A, Nikièma F, Tapily A, Sompougdou F, Diarra M, Zoungrana C, Issiaka D, Haro A, Sanogo K, Sienou A, Kaya M, Traore S, Thera I, Diarra K, Dolo A, Kuepfer I, Snell P, Milligan P, Ockenhouse C, Ofori-Anyinam O, Tinto H, Djimde A, Ouedraogo J, Dicko A, Chandramohan D, Greenwood B. The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine. Clinical Infectious Diseases 2021, 75: 613-622. PMID: 34894221, PMCID: PMC9464075, DOI: 10.1093/cid/ciab1017.Peer-Reviewed Original ResearchConceptsFirst booster doseDoses of RTSBooster doseAntibody responseSeasonal vaccinationPost-vaccination antibody titersAnti-circumsporozoite antibodiesBooster antibody responseDiminished antibody responsePrimary vaccination seriesSeasonal malaria chemopreventionSecond booster doseStrong antibody responseIncidence of malariaSubset of childrenEnzyme-linked immunosorbentVaccination seriesBooster dosesMalaria chemopreventionSevere malariaMalaria vaccineAntibody titersLower incidenceVaccinationAS01E
2020
Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS,S/AS01E vaccine, seasonal malaria chemoprevention and the combination of vaccination and chemoprevention
Chandramohan D, Dicko A, Zongo I, Sagara I, Cairns M, Kuepfer I, Diarra M, Tapily A, Issiaka D, Sanogo K, Mahamar A, Sompougdou F, Yerbanga S, Thera I, Milligan P, Tinto H, Ofori-Anyinam O, Ouedraogo J, Greenwood B. Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS,S/AS01E vaccine, seasonal malaria chemoprevention and the combination of vaccination and chemoprevention. BMJ Open 2020, 10: e035433. PMID: 32933955, PMCID: PMC7493088, DOI: 10.1136/bmjopen-2019-035433.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionClinical malariaTransmission seasonMalaria chemopreventionSeasonal vaccinationDoses of RTSWeekly active surveillancePlacebo-controlled trialPhase 3 trialMalaria transmission seasonPositive blood filmPrevalence of malariaSubsequent transmission seasonSubset of childrenCombination of vaccinationBooster doseModified intentionPrimary endpointControl vaccineFirst doseMalaria vaccineActive surveillanceCase detectionRabies vaccineHealth facilities
2018
Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules
Moïsi J, Yaro S, Kroman S, Gouem C, Bayane D, Ganama S, Meda B, Nacro B, Njanpop-Lafourcade B, Ouangraoua S, Ouedraogo I, Sakande S, Sawadogo F, Zida S, Ouedraogo J, Gessner B. Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules. Journal Of The Pediatric Infectious Diseases Society 2018, 8: 422-432. PMID: 30299491, DOI: 10.1093/jpids/piy075.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAntibodies, BacterialBurkina FasoChild, PreschoolFemaleHumansImmunization ScheduleImmunization, SecondaryImmunogenicity, VaccineImmunoglobulin GInfantMaleOpsonin ProteinsPhagocytosisPneumococcal InfectionsPneumococcal VaccinesSerogroupStreptococcus pneumoniaeVaccines, ConjugateConceptsPneumococcal conjugate vaccineMonths of ageConjugate vaccineStudy armsImmune responseDoses of PCVAge groupsDoses 2 monthsSerum immunoglobulin G concentrationBurden of morbidityStreptococcus pneumoniae infectionStrong primary immune responsesRoutine immunization programPrimary immune responseRobust memory responsesMajority of serotypesYears of ageWeeks of ageImmunoglobulin G concentrationBooster doseReactogenicity dataReactogenicity profileSatisfactory immunogenicityOpsonophagocytic activityPneumoniae infection